| __timestamp | Bristol-Myers Squibb Company | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 17763000 |
| Thursday, January 1, 2015 | 5001000000 | 22180000 |
| Friday, January 1, 2016 | 5002000000 | 37257000 |
| Sunday, January 1, 2017 | 4849000000 | 27367000 |
| Monday, January 1, 2018 | 4551000000 | 64770000 |
| Tuesday, January 1, 2019 | 4871000000 | 74986000 |
| Wednesday, January 1, 2020 | 7661000000 | 79256000 |
| Friday, January 1, 2021 | 7690000000 | 100156000 |
| Saturday, January 1, 2022 | 7814000000 | 131408000 |
| Sunday, January 1, 2023 | 7772000000 | 152946000 |
| Monday, January 1, 2024 | 8414000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bristol-Myers Squibb Company (BMY) and Dynavax Technologies Corporation (DVAX) offer a fascinating contrast in this regard. Over the past decade, BMY has consistently maintained higher SG&A expenses, peaking at approximately $7.8 billion in 2022. In contrast, DVAX's SG&A costs have been significantly lower, reaching around $153 million in 2023. This stark difference highlights BMY's expansive operations compared to DVAX's more streamlined approach. However, the trend for both companies shows a steady increase in SG&A expenses, with BMY's costs growing by about 36% from 2014 to 2023, while DVAX's expenses surged by over 760% in the same period. This data underscores the diverse strategies these companies employ in managing their operational costs.
Who Optimizes SG&A Costs Better? Sanofi or Bristol-Myers Squibb Company
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Bristol-Myers Squibb Company or GSK plc: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company vs Summit Therapeutics Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Geron Corporation
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation